Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JNCE Jounce Therapeutics (JNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Jounce Therapeutics Stock (NASDAQ:JNCE) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Jounce Therapeutics alerts:Sign Up Key Stats Today's Range$1.88▼$1.9350-Day Range$1.84▼$1.9452-Week Range$0.58▼$5.87Volume11.60 million shsAverage Volume2.46 million shsMarket Capitalization$98.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Stock News HeadlinesTaboola Partners with Jounce Media to Verify Ad Inventory is Free From Made for Advertising (MFA) PropertiesOctober 2, 2024 | markets.businessinsider.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusNovember 27, 2023 | bizjournals.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 15, 2024 | Colonial Metals (Ad)Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 19, 2023 | tmcnet.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 18, 2023 | finance.yahoo.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaSeptember 5, 2023 | tmcnet.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comSee More Headlines JNCE Stock Analysis - Frequently Asked Questions How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. When did Jounce Therapeutics IPO? Jounce Therapeutics (JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK). Company Calendar Last Earnings11/04/2021Today11/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,920,000.00 Net MarginsN/A Pretax Margin-61.93% Return on Equity-30.90% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio8.37 Quick Ratio8.37 Sales & Book Value Annual Sales$82 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book0.53Miscellaneous Outstanding Shares52,630,000Free Float48,993,000Market Cap$98.94 million OptionableOptionable Beta0.75 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:JNCE) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jounce Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JNCE Stock Alerts